GHRH-R antagonists MIA-602, MIA-606, and MIA-690 inhibit prostate cancer progression by inducing apoptosis and reducing proliferation.
Background
Therapeutic strategies for prostate cancer aim to transform aggressive phenotypes into a more manageable, chronic condition. Current treatments often have significant side effects or lead to resistance, creating a need for novel approaches that target key progression pathways. The growth hormone-releasing hormone (GHRH) and its receptor (GHRH-R) are implicated in tumor growth, making them an attractive therapeutic target. Antagonizing this receptor could disrupt critical cancer processes like cell proliferation, adhesion, migration, and angiogenesis. This study investigates a new series of GHRH-R antagonists to evaluate their potential to inhibit molecular machinery involved in prostate cancer progression.
Study Design
The study used three human prostate cell lines: a non-cancerous line (RWPE-1) and two cancerous lines (LNCaP, PC3). Researchers treated these cells with three new GHRH-R antagonists: MIA-602, MIA-606, and MIA-690. They analyzed the effects on cell viability, proliferation (via PCNA expression), cell adhesion, migration (via wound closure assay), and apoptosis (cell cycle analysis for SubG0 phase). The molecular impact was assessed by measuring levels of key proteins involved in cancer progression, including E-cadherin, β-catenin, Bcl2, Bax, p53, matrix metalloproteinases (MMP2, MMP9), and VEGF.
Results
The GHRH-R antagonists successfully decreased cell viability and reduced proliferation in both LNCaP and PC3 cancer cell lines. The antagonists also induced a time-dependent increase in cell adhesion across all three cell lines tested. In migration assays, the antagonists retarded wound closure, indicating reduced cell motility.
The most significant effect on migration was observed with MIA-690 in the highly aggressive
PC3cell line.
Furthermore, treatment with the antagonists led to a large number of cells entering the SubG0 phase of the cell cycle, a hallmark of apoptosis. This increase in apoptotic cells was particularly noted in the PC3 cell line. These findings collectively demonstrate that antagonizing the GHRH-R disrupts multiple key processes essential for tumor progression in prostate cancer models.
Key Findings
- GHRH-R antagonists MIA-602, MIA-606, and MIA-690 decreased cell viability and proliferation in LNCaP and PC3 prostate cancer cells.
- The antagonists caused a time-dependent increase in cell adhesion in all three tested cell lines (RWPE-1, LNCaP, PC3).
- Cell migration was retarded by the antagonists, with MIA-690 showing the highest inhibition of wound closure in PC3 cells.
- A large number of PC3 cells treated with GHRH-R antagonists entered the SubG0 phase, indicating an increase in apoptosis.
Why It Matters
This in vitro research provides strong preclinical evidence for a new class of compounds in the fight against prostate cancer. The results suggest that GHRH-R antagonists like the MIAMI series could be a powerful tool to halt or slow tumor progression by simultaneously targeting proliferation, migration, and survival. For clinicians and researchers, this opens a new avenue for developing therapies, potentially for aggressive or treatment-resistant prostate cancer. While this is an early-stage cell line study, the multi-pronged mechanism of action is promising. These findings support the continued development of GHRH-R antagonists as a potential future therapeutic strategy for prostate cancer, aiming to convert it into a manageable chronic disease rather than a terminal one.
